10-Q: NW Bio Q3 2025: Losses Mount, Advent Acquired, UK MAA Review Continues

Northwest Biotherapeutics reported increased net losses and a going concern warning for Q3 2025, while advancing its UK regulatory review and acquiring Advent BioServices.

Summary

• Net loss for the nine months ended September 30, 2025, increased to $61.6 million from $55.6 million in the prior year period.
• Cash used in operating activities for the nine months ended September 30, 2025, decreased to $30.0 million from $36.8 million in the prior year.
• Cash and cash equivalents increased to $4.6 million as of September 30, 2025, from $2.2 million at December 31, 2024.
• Total liabilities significantly increased to $125.9 million as of September 30, 2025, from $105.7 million at December 31, 2024.
• The company completed the acquisition of Advent BioServices Ltd., a related-party CDMO, on October 24, 2025.
• The Marketing Authorization Application (MAA) for DCVax-L in glioblastoma is under review by the UK's MHRA, with no interim announcements planned.
• The company is restarting its DCVax-Direct program for inoperable tumors, with several SOW 8 milestones completed but unpaid, totaling $1.9 million accrued liability.
• A settlement agreement was reached in the Delaware Action litigation, resulting in the cancellation of 17% of challenged 2020 options and a $2.25 million payment to the company from insurers.
• The company continues to face substantial doubt about its ability to continue as a going concern due to recurring operating losses and insufficient liquidity.

Sentiment

Score: 3

Explanation: The company continues to face significant financial challenges, including increasing losses, a substantial going concern warning, and growing liabilities. While there are operational advancements like the Advent acquisition and MAA review, these are overshadowed by the persistent need for financing and the lack of near-term revenue. The legal settlement is a positive, but the overall financial health remains precarious.

Positives

• Net cash used in operating activities decreased to $30.0 million for the nine months ended September 30, 2025, from $36.8 million in the prior year period.
• Cash and cash equivalents increased to $4.6 million as of September 30, 2025, from $2.2 million at December 31, 2024.
• The acquisition of Advent BioServices Ltd. on October 24, 2025, brings fixed assets, cryostorage, and intellectual property in-house, with 19 million of the company's securities reverting back.
• A settlement was reached in the Delaware Action litigation, leading to the cancellation of 17% of challenged 2020 options and a $2.25 million payment to the company from its insurance carriers.
• Progress was made on the Sawston, UK facility, including sourcing two major pieces of equipment for less than half price, avoiding a 10-12 month procurement backlog.
• The DCVax-Direct program is being restarted, with manufacturing and product-related IND sections already completed.
• The company finalized the selection of a US GMP manufacturing location for in-licensed technologies and is proceeding with contract negotiations and hiring.

Negatives

• Net loss for the nine months ended September 30, 2025, increased to $61.6 million from $55.6 million in the prior year period.
• Total liabilities significantly increased to $125.9 million as of September 30, 2025, from $105.7 million at December 31, 2024.
• Stockholders deficit increased to $(108.6) million as of September 30, 2025, from $(94.5) million at December 31, 2024.
• Revenues decreased to $706,000 for the nine months ended September 30, 2025, from $1.2 million in the prior year period.
• The company recognized $15.8 million in debt extinguishment losses for the nine months ended September 30, 2025, up from $9.9 million in the prior year.
• A $1.0 million loss contingency was recognized related to the exit terms of a UK office lease.
• Related party accounts payable and accrued expenses to Advent BioServices increased to $9.8 million as of September 30, 2025, from $4.5 million at December 31, 2024.
• Several SOW 8 milestones for the DCVax-Direct program, totaling $1.9 million, have been completed but remain unpaid and are accrued liabilities.

Risks

• Substantial doubt about the company's ability to continue as a going concern for at least one year due to recurring operating losses and operating cash flow deficits.
• Inability to generate material revenue in the near future from product sales.
• Dependence on obtaining additional equity and/or debt financing, which may not be available on favorable terms or at all.
• Risks and uncertainties typical of biotechnology companies focused on R&D and clinical trials without commercial products.
• Potential for significant increases in expense levels from being a publicly-traded company or from expansion of operations.
• Market risk related to derivatives, debt, and equity-linked instruments, though currently considered immaterial for interest rate changes.
• Ongoing legal proceedings, such as the market manipulation lawsuit, could be costly and time-consuming, even if the company plans to pursue it vigorously.
• The MAA for DCVax-L is still under regulatory review, with no guarantee of approval.
• The DCVax-Direct program is being restarted, indicating prior challenges or delays in its development.

Future Outlook

The company expects to continue incurring annual losses for the foreseeable future and does not anticipate generating material revenue from product sales in the near term. It will need to obtain additional equity and/or debt financing to fund operations, capital expenditures, and working capital until significant revenues are achieved. The company plans to conduct clinical trials of DCVax-L for other solid tumor cancers and preparations for Phase II trials of DCVax-Direct as resources permit.

Management Comments

• "We do not expect to generate material revenue in the near future from the sale of products and are subject to all of the risks and uncertainties that are typically faced by biotechnology companies that devote substantially all of their efforts to research and development (R&D) and clinical trials and do not yet have commercial products."
• "The Company expects to continue incurring annual losses for the foreseeable future."
• "The Companys existing liquidity is not sufficient to fund its operations, anticipated capital expenditures, working capital and other financing requirements until the Company reaches significant revenues."
• "If the Company attempts to obtain additional equity or debt financing, the Company cannot assume that such financing will be available to the Company on favorable terms, or at all."
• "The Company does not plan to make any interim announcements while its MAA is going through the regulatory process. The Company plans to announce the results when the regulatory review and decision-making is finished."
• "The Company believes that the discovery process may yield very important information, and the Company plans to continue pursuing the case vigorously."

Industry Context

Northwest Biotherapeutics operates in the highly capital-intensive and high-risk biotechnology sector, specifically in cancer immunotherapy. The company's focus on dendritic cell-based therapies (DCVax platform) places it in a competitive field with other companies developing novel immunotherapies. The ongoing MAA review in the UK for DCVax-L highlights the significant regulatory hurdles inherent in bringing new cancer treatments to market. The acquisition of Advent BioServices, a CDMO, reflects a trend towards vertical integration or securing critical manufacturing capabilities, especially for complex cell therapies, to control costs and supply chains. The company's recurring losses and "going concern" warning are common for pre-revenue biotech firms, emphasizing the long development cycles and substantial investment required before commercialization.

Comparison to Industry Standards

• The company's "going concern" warning is a significant red flag, indicating a higher financial risk compared to more established biotech firms with commercial products or robust funding.
• The long development timeline for DCVax-L (Phase 3 completed, MAA submitted in Dec 2023, still under review) is typical for complex cell therapies in oncology, which often face extensive regulatory scrutiny.
• The acquisition of a contract development and manufacturing organization (CDMO) like Advent BioServices is a strategic move seen across the biotech industry to gain greater control over manufacturing processes and intellectual property, similar to how larger pharmaceutical companies often internalize key production capabilities or secure long-term supply agreements.
• The reliance on equity and debt financing to cover operating losses is standard for pre-revenue biotechnology companies, but the increasing debt extinguishment losses and the need for continuous capital raises suggest a more challenging funding environment or less favorable terms compared to peers with stronger clinical data or closer proximity to market approval.
• The company's R&D expenses, while decreasing slightly, remain substantial, reflecting the high costs associated with advanced clinical trials and regulatory submissions in oncology, comparable to other companies in late-stage development.

Management Changes

Corporate Governance

Legal Proceedings

• **Market Manipulation Lawsuit:** The company filed a complaint on December 1, 2022, against certain market makers for alleged stock manipulation. The case is in the discovery stage, with the company vigorously pursuing documents and information. The Magistrate Judge previously found the company adequately pled market manipulation but not enough details for calculating actual damages (loss causation), which the company subsequently re-pled.
• **Delaware Action (2020 Option Grants):** A settlement agreement was reached on October 9, 2025, with Lead Plaintiff F. Glenn Schaeffer. Under the terms, 17% of the challenged 2020 options will be cancelled, and the company's insurance carriers will pay $2.25 million to the company. The settlement and any award of fees are subject to court approval.

Related Party Transactions

• **Advent BioServices Ltd.:** Prior to its acquisition on October 24, 2025, Advent was a related party providing product development, manufacturing, cryostorage, and distribution services.
• **Manufacturing Services Agreement (MSA):** With Advent for DCVax-L production in London (entered May 14, 2018).
• **Ancillary Services Agreement:** With Advent for development and manufacturing at the Sawston facility (entered November 18, 2019, extended to July 2026).
• **Statement of Work #8 (SOW 8):** With Advent for establishing the DCVax-Direct program in the U.K. and manufacturing products. Several milestones completed but unpaid, resulting in $1.9 million in accrued liabilities to Advent as of September 30, 2025.
• **Sub-lease Agreement:** With Advent for a portion of the Sawston facility space (entered December 31, 2021).
• **Related Party Accounts Payable:** As of September 30, 2025, $9.8 million was owed to Advent BioServices, including $1.1 million for 1.5 million shares related to the MAA submission milestone that had not been issued.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from ongoing equity financing and convertible debt conversions. The "going concern" warning indicates high financial risk. The settlement of the Delaware Action reduces potential dilution from challenged options and brings a cash payment from insurers.
• **Employees:** The unexpected passing of a Senior VP and General Counsel may create leadership transition challenges. The acquisition of Advent BioServices could impact employees of both entities through integration.
• **Customers/Patients:** Progress on MAA review for DCVax-L and restarting DCVax-Direct program offers potential future treatment options.
• **Creditors:** Increased total liabilities and reliance on debt financing indicate higher credit risk. Debt extinguishment losses reflect unfavorable debt restructuring.
• **Suppliers:** Advent BioServices, a key supplier, has been acquired, potentially streamlining supply chains for DCVax products.

Next Steps

• Continue active engagement in the MAA review process by the MHRA for DCVax-L.
• Announce MAA results when the regulatory review and decision-making is finished.
• Restart the DCVax-Direct program for inoperable tumors.
• Conduct clinical trials of DCVax-L for other solid tumor cancers when resources permit.
• Work on preparations for Phase II trials of DCVax-Direct as resources permit.
• Continue refining the design and engineering of the simplified C lab at the Sawston, UK facility and prepare for construction works.
• Source key equipment for the C lab.
• Finalize contract negotiations and allocate operational responsibilities for the selected US GMP manufacturing location.
• Continue the hiring process for the initial core operating team for the US manufacturing location.
• Explore potential for expanded access/compassionate use programs in the US, particularly under state laws, and pursue multiple potential hospital arrangements.
• Continue analyses to select additional treatment elements from in-licensed portfolios for new DCVax-Direct clinical trial designs.
• Continue vigorous pursuit of the market manipulation lawsuit, including further ramping up discovery.
• Complete definitive settlement documentation for the Delaware Action litigation.
• Plaintiff intends to apply to the Court for an award of attorneys' fees and expenses in connection with the Delaware Action.
• Obtain additional equity and/or debt financing to fund operations.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by a substantial "going concern" warning, increasing net losses, and a significant rise in total liabilities. While operational progress like the Advent acquisition and MAA review are noted, they are overshadowed by the precarious financial position and the explicit need for continuous, potentially dilutive, financing. The history of debt extinguishment losses and the reliance on converting debt to equity at unfavorable terms further erode shareholder value. The stock trades on OTCQB, indicating lower liquidity and higher risk. A seasoned investor would view the persistent financial instability and the explicit going concern warning as critical indicators of high risk and potential for further capital erosion, warranting a strong sell recommendation.

Keywords

Biotechnology, Immunotherapy, Cancer Treatment, DCVax-L, Glioblastoma, DCVax-Direct, SEC Filing, 10-Q, Financial Results, Clinical Trials, Regulatory Approval, MAA, MHRA, Going Concern, Debt Financing, Equity Financing, Advent BioServices, Acquisition, Market Manipulation Lawsuit